Abstract: An intracranial photobiomodulation system (IPS) comprises a removeable light therapy implant and a permanent sheath. The removeable light therapy implant is adapted to be removably secured to the sheath and has (i) a support arm having a proximal end and a distal end, and (ii) at least one light source located along the support arm. The at least one light source is configured to emit light of at least one wavelength and at least one intensity. The permanent sheath comprises a shell and a sleeve. The shell is adapted to be permanently secured to a patient's scalp and the sleeve is made of a transparent material that allows light to pass therethrough and has a proximal opening and a distal closed tip, the proximal opening is adapted to removably receive the support arm and light source of the removeable light therapy implant.

Abstract: An intracranial photobiomodulation system (IPS) comprises a removeable light therapy implant and a permanent sheath. The removeable light therapy implant is adapted to be removably secured to the sheath and has (i) a support arm having a proximal end and a distal end, and (ii) at least one light source located along the support arm. The at least one light source is configured to emit light of at least one wavelength and at least one intensity. The permanent sheath comprises a shell and a sleeve. The shell is adapted to be permanently secured to a patient's scalp and the sleeve is made of a transparent material that allows light to pass therethrough and has a proximal opening and a distal closed tip, the proximal opening is adapted to removably receive the support arm and light source of the removeable light therapy implant.

Abstract: Disclosed are phenothiazine compounds which reduce Abeta toxicity in vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhage in vivo toxicity as indicated by preserved motor and cognitive function, and SARS-CoV-2 replication. Also disclosed are methods of use thereof for the treatment of disease in a subject in need thereof.

Abstract: An intracranial photobiomodulation system (IPS) comprises a removeable light therapy implant and a permanent sheath. The removeable light therapy implant is adapted to be removably secured to the sheath and has (i) a support arm having a proximal end and a distal end, and (ii) at least one light source located along the support arm. The at least one light source is configured to emit light of at least one wavelength and at least one intensity. The permanent sheath comprises a shell and a sleeve. The shell is adapted to be permanently secured to a patient's scalp and the sleeve is made of a transparent material that allows light to pass therethrough and has a proximal opening and a distal closed tip, the proximal opening is adapted to removably receive the support arm and light source of the removeable light therapy implant.